Faculty Disclosures

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the- education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for balance, scientific objectivity of studies referenced and patient care recommendations.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Hart – Director of Research, Florida Cancer Specialists, Naples, Florida; Speakers Bureau: AstraZeneca Pharmaceuticals LP

Dr Hagemeister – Professor of Medicine, The University of Texas MD Anderson Cancer Center, Department of Lymphoma/ Myeloma, Houston, Texas; Consulting Fees: Biogen Idec, GlaxoSmithKline; Speakers Bureau: Biogen Idec, Genentech BioOncology, GlaxoSmithKline, Ortho Biotech Products LP

The scientific staff and consultants for Research To Practice are involved in the development and review content for educational activities and report the following real or apparent conflicts of interest for themselves their spouses/partners) that have been resolved through a peer review process: James E Boyer, MD, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD – no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP – shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by education grants from Biogen Idec and Genentech BioOncology.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

 

NHLUpdate.com Patient Education Audio Series